Cinclus Pharma reached enrollment target in Phase III study
The HEEALING1 study evaluates linaprazan glurate for erosive GERD, with topline results expected in Q4 2026.
See the latest news and media coverage for Cinclus Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage pharmaceutical company
cincluspharma.comLast updated
In short: Cinclus Pharma achieved the enrollment target for its Phase III study of linaprazan glurate and secured €28 million in growth financing.
The HEEALING1 study evaluates linaprazan glurate for erosive GERD, with topline results expected in Q4 2026.
The trial evaluates linaprazan glurate for erosive GERD, with topline results expected Q4 2026.
On 21 May 2026 Cinclus re-elected and appointed board members, approved fees and remuneration report, authorized share issues, adopted a 2026–2029 performance share program, and resolved no dividend.
Enrollment progressing well; topline results expected in Q4 2026. Financial position strengthened.
Find the latest Cinclus Pharma Holding AB news today, including breaking Cinclus Pharma Holding AB stock news, key announcements, and market-moving updates. Summarize CINPHA's latest...
"Patient enrollment in our first Phase III study has continued to progress well and we have good visibility on the timeline with expected topline results...
On Wednesday afternoon, Pareto brokered a position worth nearly 25 million kronor in Cinclus Pharma at a big discount. The share plummets 18 percent. In the newsletter Toppnyheter receives...
The pharmaceutical development company Cinclus Pharma has entered into a financing agreement with Claret Capital Partners for up to 28 million euros. The capital will...
Track Cinclus Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.